PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 77 filers reported holding PROQR THRAPEUTICS N V in Q4 2021. The put-call ratio across all filers is 2.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,791,000 | -91.3% | 3,084,150 | -23.2% | 0.00% | -100.0% |
| Q4 2021 | $32,182,000 | -28.2% | 4,017,760 | -24.9% | 0.01% | -37.5% |
| Q3 2021 | $44,796,000 | +79.5% | 5,351,845 | +44.5% | 0.01% | +100.0% |
| Q2 2021 | $24,959,000 | +11.2% | 3,703,031 | +9.1% | 0.00% | 0.0% |
| Q1 2021 | $22,436,000 | +54.6% | 3,394,246 | -1.8% | 0.00% | +33.3% |
| Q4 2020 | $14,514,000 | -35.8% | 3,455,765 | -26.8% | 0.00% | -40.0% |
| Q3 2020 | $22,620,000 | -23.6% | 4,722,240 | -3.0% | 0.01% | -28.6% |
| Q2 2020 | $29,600,000 | +6.7% | 4,868,415 | -3.6% | 0.01% | 0.0% |
| Q1 2020 | $27,736,000 | -49.1% | 5,052,291 | -8.1% | 0.01% | -36.4% |
| Q4 2019 | $54,457,000 | +1242.0% | 5,495,128 | +679.9% | 0.01% | +1000.0% |
| Q3 2019 | $4,058,000 | +60.1% | 704,596 | +153.0% | 0.00% | 0.0% |
| Q2 2019 | $2,535,000 | – | 278,523 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 1,922,570 | $19,053,000 | 7.16% |
| DAFNA Capital Management LLC | 1,114,000 | $11,040,000 | 3.79% |
| RTW INVESTMENTS, LP | 4,779,135 | $47,361,000 | 1.79% |
| Kerrisdale Advisers, LLC | 448,880 | $4,448,000 | 1.57% |
| SPHERA FUNDS MANAGEMENT LTD. | 805,000 | $7,978,000 | 0.66% |
| Artal Group S.A. | 1,300,000 | $12,883,000 | 0.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,571,319 | $45,302,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 221,360 | $2,194,000 | 0.09% |
| COWEN AND COMPANY, LLC | 103,727 | $1,028,000 | 0.09% |
| FRANKLIN STREET ADVISORS INC /NC | 60,000 | $595,000 | 0.07% |